SITE012-0015

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-03-02

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-03-22 (study day 4); relationship: not assessed

severe assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-12 (study day 55); relationship: N

severe serious assessed

Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-20 (study day 94); relationship: N; serious criteria: life-threatening

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-07-04 (study day 108); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-16 (study day 151); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-02 (study day 168); relationship: not assessed

severe assessed

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-04 (study day 170); relationship: not assessed

Data queries

No data queries.